Biofrontera Revenue

In the year 2025, Biofrontera had annual revenue of $41.71M with 11.75% growth. Biofrontera had revenue of $17.10M in the quarter ending December 31, 2025, with 36.16% growth.

Revenue (ttm)

$41.71M

Revenue Growth

+11.75%

P/S Ratio

0.31

Revenue / Employee

$443,670

Employees

Market Cap

13.05M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	41.71M	4.38M	11.75%
Dec 31, 2024	37.32M	3.25M	9.54%
Dec 31, 2023	34.07M	5.40M	18.82%
Dec 31, 2022	28.67M	4.57M	18.98%
Dec 31, 2021	24.10M	5.25M	27.86%
Dec 31, 2020	Pro	Pro	Pro
Dec 31, 2019	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Aytu BioPharma	62.64M
cbdMD	19.09M
China Pharma Holdings	4.14M
TherapeuticsMD	3.02M
China SXT Pharmaceuticals	1.54M
Akanda	836.66K
BioXcel Therapeutics	642.00K
Gelteq	270.85K

Revenue Rankings

BFRI News

5 weeks ago - Biofrontera Earnings Call Transcript: Q4 2025 - Transcripts
5 weeks ago - Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - GlobeNewsWire
7 weeks ago - Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 - GlobeNewsWire
7 weeks ago - Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris - GlobeNewsWire
2 months ago - U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable - GlobeNewsWire
2 months ago - Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities - GlobeNewsWire
2 months ago - Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma - GlobeNewsWire
2 months ago - Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint - GlobeNewsWire

More News